BRIEF-Oryzon Announces A New Financing Through A Convertible Bond Program For A Total Amount Up To ?20 Million Over 30 Months

BY Reuters | CORPORATE | 07/05/22 08:24 AM EDT

July 5 (Reuters) - Oryzon Genomics SA:

* ORYZON ANNOUNCES A NEW FINANCING THROUGH A CONVERTIBLE BOND PROGRAM FOR A TOTAL AMOUNT UP TO ?20 MILLION OVER 30 MONTHS

* ORYZON GENOMICS SA - FUNDING PROVIDED BY NICE & GREEN SA, A SWISS INSTITUTIONAL INVESTOR

* ORYZON GENOMICS - INITIAL EXECUTION OF FIRST TRANCHE OF EUR 8 MILLION, PLUS 3 OPTIONAL ADDITIONAL TRANCHES OF EUR 4 MILLION TO BE EXECUTED IN FUTURE, AT CO'S REQUEST Source text for Eikon: Further company coverage:

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.

fir_news_article